Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats
文献类型：期刊论文
| 作者 | Clozel, M; Hess, P; Rey, M; Iglarz, M; Binkert, C; Qiu, CB |
| 刊名 | EXPERIMENTAL BIOLOGY AND MEDICINE
 |
| 出版日期 | 2006-06 |
| 卷号 | 231期号:6页码:967-973 |
| 关键词 | bosentan endothelin nitric oxide pulmonary hypertension sildenafil |
| ISSN号 | 1535-3702 |
| 文献子类 | Article; Proceedings Paper |
| 英文摘要 | The dual endothelin receptor antagonist, bosentan, and the phosphodiesterase inhibitor, sildenafil, are efficacious in experimental and clinical pulmonary hypertension (PHT). The effects of bosentan, slidenafil, and their combination were evaluated in rats with monocrotaline (MCT)-induced PHT. A first group consisted of control rats with no MCT injection. Four other groups of rats received MCT subcutaneously and were assigned to receive no treatment, 300 mg/kg/day bosentan as food admix, 100 mg/kg/day sildenafil in drinking water, or their combination for 4 weeks. The doses of bosentan and sildenafil were the maximally effective doses based on a dose-range-finding study. Mortality was 0%, 53%, 11%, 11%, and 0%, respectively, in the five different groups. Bosentan and sildenafil significantly attenuated the increase in mean pulmonary arterial pressure, and the combination had an additional effect. Similarly, bosentan, sildenafil, and, to a greater extent, their combination significantly reduced right ventricular (FIV) hypertrophy. Bosentan, but not sildenafil, decreased norepinephrine and BNP plasma concentrations, reduced kidney weight, and normalized systemic hemodynamics. In conclusion, bosentan and sildenafil are efficacious in rats with chronic PHT, and their combination shows an additional effect for decreasing pulmonary arterial pressure, reducing plasma catecholamines, maintaining body weight, and reducing mortality. |
| WOS关键词 | RECEPTOR ANTAGONIST BOSENTAN ; CHRONIC HEART-FAILURE ; ARTERIAL-HYPERTENSION ; ENDOTHELIAL DYSFUNCTION ; NITRIC-OXIDE ; MEDIATED VASODILATION ; NATRIURETIC PEPTIDE ; IN-VIVO ; ACTIVATION ; ISCHEMIA |
| WOS研究方向 | Research & Experimental Medicine |
| 语种 | 英语 |
| WOS记录号 | WOS:000237934600053 |
| 出版者 | SOC EXPERIMENTAL BIOLOGY MEDICINE |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/273576]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Clozel, M |
| 作者单位 | 1.Actel Pharmaceut Ltd, CH-4123 Allschwil, Switzerland 2.Chinese Acad Sci, Shanghai Inst Mat Med, Dept Pharmacol, Shanghai 200031, Peoples R China |
| 推荐引用方式 GB/T 7714 | Clozel, M,Hess, P,Rey, M,et al. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats[J]. EXPERIMENTAL BIOLOGY AND MEDICINE,2006,231(6):967-973. |
| APA | Clozel, M,Hess, P,Rey, M,Iglarz, M,Binkert, C,&Qiu, CB.(2006).Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats.EXPERIMENTAL BIOLOGY AND MEDICINE,231(6),967-973. |
| MLA | Clozel, M,et al."Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats".EXPERIMENTAL BIOLOGY AND MEDICINE 231.6(2006):967-973. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。